Overview

Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma.

This research study is investigating using a new blood test to decide when to give a drug called tebentafusp. Tebentafusp has been used in clinical trials in patients with advanced cutaneous and uveal melanoma. This study is designed to determine if tebentafusp can help patients with cutaneous or uveal melanoma live longer.

Eligibility

Inclusion Criteria:

        A patient will be eligible for inclusion in cohort A or B if all of the following criteria
        apply:
          1. Uveal or cutaneous melanoma with MRD detected in molecular screening.
          2. Written (signed and dated) informed consent.
          3. Male or female, Age 18 years and above.
          4. Life expectancy of at least 3 months.
          5. ECOG performance score of 0 or 1.
          6. No evidence of metastatic disease on a CT scan of neck/thorax/abdomen/pelvis for
             cohorts A and B and also on MRI liver for uveal melanoma for cohort B.
          7. Those receiving prior immunotherapy must have recovered from any immune-mediated
             adverse events (≤ grade 1) other than endocrinopathies on stable replacement therapy.
          8. Haematological and biochemical indices within normal ranges (refer to protocol for
             ranges)
        Exclusion Criteria:
        A patient will not be eligible for tebentafusp administration if any of the following
        apply:
          1. Treatment with any other investigational agent, or participation in another
             interventional clinical trial within 28 days prior to enrolment.
          2. Uveal or cutaneous melanoma patients who present radiologically or clinically
             detectable disease during screening.
          3. Active infection requiring systemic antibiotic therapy. Patients requiring systemic
             antibiotics for infection must have completed therapy before Screening is initiated
          4. Other psychological, social or medical condition, physical examination finding or a
             laboratory abnormality that the Investigator considers would make the patient a poor
             trial candidate or could interfere with protocol compliance or the interpretation of
             trial results.
          5. Any other active malignancy, with the exception of malignancies that were treated
             curatively and have not recurred within 2 years after completion of treatment;
             completely resected basal cell and squamous cell skin cancers; any malignancy
             considered to be indolent and that has never required therapy; and completely resected
             carcinoma in situ of any type
          6. Patients who are known to be serologically positive for Hepatitis B, Hepatitis C or
             HIV. This study does not require testing to confirm eligibility unless clinically
             indicated.
          7. Clinically significant cardiac disease or impaired cardiac function (New York Heart
             Association grade ≥ 2), including myocardial infarction or unstable angina pectoris
             within 6 months of screening.
          8. Active autoimmune disease or a documented history of autoimmune disease within 3 years
             of screening (diabetes mellitus, vitiligo, managed hypothyroidism, psoriasis and
             managed asthma are not exclusions).
          9. Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For
             cytotoxic agents that have major delayed toxicity and any prior immunotherapy
             approach, 4 weeks is indicated as washout period
         10. Presence of NCI CTCAE ≥ grade 2 toxicity (except alopecia, peripheral neuropathy, and
             ototoxicity, which are excluded if ≥ NCI CTCAE grade 3) due to prior cancer therapy.
         11. Patients currently requiring chronic, systemic corticosteroid therapy at any dose for
             longer than 2 weeks. Replacement treatment for pituitary or adrenal insufficiency is
             permitted. Local steroid therapies (e.g. otic, ophthalmic, intra-articular, or inhaled
             medications) are acceptable.
         12. Use of any live vaccines against infectious diseases within 4 weeks of initiation of
             study treatment. Non-live vaccination (e.g. influenza) are permitted anytime during
             treatment.
         13. Major surgery as defined by the investigator within 2 weeks of the first dose of study
             treatment (minimally invasive procedures such as bronchoscopy, insertion of a central
             venous access device, and insertion of a feeding tube are not considered major
             surgery).
         14. Pregnant or lactating women, or women of childbearing potential unless effective
             methods of contraception are used.
         15. Women of child-bearing potential who are sexually active with a non-sterilized male
             partner, defined as all women physiologically capable of becoming pregnant, unless
             they are using highly effective contraception during study treatment, and must agree
             to continue using such precautions for 6 months after the final dose of
             investigational product; cessation of birth control after this point should be
             discussed with a responsible physician.
         16. Male patients must be surgically sterile or use double barrier contraception method
             from enrolment through treatment and for 6 months following administration of the last
             dose of study drug.